Skip to main navigation
  • Careers
  • Partnerships & Business Development
  • Contact Us
Link to  Esperion Therapeutics, Inc. Homepage
  • Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Ethics and Compliance
    • Corporate Governance & Committee Composition
  • Products
  • Science
    • Unmet Need
    • Scientific Resources
    • Scientific Advisory Board
    • Pipeline
    • Grants
  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs

Newsroom

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Sep 19, 2025
PDF Version
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
Aug 29, 2025
PDF Version
Esperion to Participate in Upcoming September Investor Conferences
Aug 26, 2025
PDF Version
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 07, 2025
PDF Version
Correcting and Replacing: Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
Aug 05, 2025
PDF Version
  • First page «
  • Previous page ‹
  • …
  • Page 5
  • Page 6
  • Current page 7
  • Page 8
  • Page 9
  • …
  • Next page ›
  • Last page »

Media Information

To speak with a member of our PR team, or to schedule an interview, please contact Esperion Corporate Communications by phone at +1 734-887-3903, or by email at corporateteam@esperion.com.


 
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

 
Corporate Inquiries & Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

 

Email Alerts

  • OUR COMPANY
  • About Us
  • Leadership Team
  • Board of Directors
  • Ethics and Compliance
  • Corporate Governance & Committee Composition
  • PRODUCTS
  • SCIENCE
  • Unmet Need
  • Scientific Resources
  • Scientific Advisory Board
  • Pipeline
  • Grants
  • CAREERS
  • Partnerships & Business Development
  • INVESTORS & MEDIA
  • Overview
  • Newsroom
  • Events
  • Financial Information
  • Stock Information & Analyst Coverage
  • FAQs
  • Contact Us
Great place to work certified | JUN 2024 - JUN 2025 | USA

All trademarks and trade names are the property of their respective owners.

© 2026 Esperion Therapeutics, Inc. All rights reserved.

  • Privacy Policy
  • Terms of Use
  • Accessibility Statement
  • Social Media Community Guidelines
  • facebook
  • instagram
  • linkedin
  • twitter
  • rss
Search Investors